Nuvectis Pharma, Inc.(NVCT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
NVCT Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Nuvectis Pharma, Inc. (NVCT), a Healthcare sector company. NVCT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Nuvectis Pharma, Inc. reports net income of $-6.0M, free cash flow of $-6.5M. Top institutional holders of NVCT by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, IRIDIAN ASSET MANAGEMENT /CT, based on the most recent SEC filings. NVCT trades on the Nasdaq exchange and files with the SEC under CIK 1875558. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NVCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nuvectis Pharma, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-6.0M
Free Cash Flow
Q1 2026
$-6.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+0.4% YoYOperating Income
-3.2% YoYEPS (Diluted)
+26.5% YoYTotal Assets
-8.8% YoYOp. Cash Flow
+9.7% YoY| Metric | FY 2024 | FY 2022 | FY 2021 |
|---|---|---|---|
| Net Income | $-19.0M +0.4% | $-19.1M -48.1% | $-12.9M |
| Operating Income | $-19.8M -3.2% | $-19.2M -49.2% | $-12.9M |
| EPS (Diluted) | $-1.11 +26.5% | $-1.51 +50.0% | $-3.02 |
| Total Assets | $18.6M -8.8% | $20.4M +206.5% | $6.7M |
| Operating Cash Flow | $-12.2M +9.7% | $-13.6M -42.7% | $-9.5M |
AI Insight: NVCT Financial Trends
Nuvectis burns cash with no revenue, equity eroding despite capital raises; operating losses remain stubbornly high.
• Operating losses widened from $5M (Q2 2024) to $8M (Q3 2025, Q4 2025), showing deteriorating burn rate before modest recovery to $6M in Q1 2026.
• Operating cash flow worsened to $7M negative in Q1 2026, worst quarter in dataset, indicating accelerating cash consumption.
• Equity volatility reflects capital raises (spiked to $24M in Q3 2025) offset by continued losses; currently $14M in Q1 2026.
⚠ No revenue generated across all eight quarters—drug candidate(s) not yet commercialized. Runway dependent entirely on funding.
⚠ Net losses accelerating (Q1 2026 $6M) after peak $7M in Q2–Q4 2025; equity cushion eroding despite fundraising.
AI Insight: NVCT Ratio Trends
ROE deteriorated to -170.2% in Q1 2026 from -101.8% in Q1 2025, indicating worsening losses relative to equity.
• ROE declined from -101.8% in Q1 2025 to -170.2% in Q1 2026, showing deepening losses.
• ROA weakened from -70.7% in Q1 2025 to -95.3% in Q1 2026, reflecting deteriorating asset efficiency.
⚠ No operational metrics available across all periods — company appears to be pre-revenue biotech with limited visibility.
⚠ TTM ROE of -191.0% versus Q1 2026 quarterly -170.2% suggests potential seasonal or one-off loss impact.
Get alerted when NVCT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Nuvectis Pharma, Inc. including:
Top Institutional Holders of NVCT
BlackRock, Inc.
$5.9M764,441 shVANGUARD CAPITAL MANAGEMENT LLC
$5.1M659,879 shIRIDIAN ASSET MANAGEMENT LLC/CT
$5.0M651,757 shOccam Crest Management LP
$3.1M407,147 shGEODE CAPITAL MANAGEMENT, LLC
$3.0M384,105 shBALDWIN WEALTH PARTNERS LLC/MA
$2.9M378,625 shSTATE STREET CORP
$1.3M166,516 shNORTHERN TRUST CORP
$960.2K124,212 shVANGUARD FIDUCIARY TRUST CO
$887.7K114,842 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$813.9K105,286 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $5.9M | 764,441 |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.1M | 659,879 |
| IRIDIAN ASSET MANAGEMENT LLC/CT | $5.0M | 651,757 |
| Occam Crest Management LP | $3.1M | 407,147 |
| GEODE CAPITAL MANAGEMENT, LLC | $3.0M | 384,105 |
| BALDWIN WEALTH PARTNERS LLC/MA | $2.9M | 378,625 |
| STATE STREET CORP | $1.3M | 166,516 |
| NORTHERN TRUST CORP | $960.2K | 124,212 |
| VANGUARD FIDUCIARY TRUST CO | $887.7K | 114,842 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $813.9K | 105,286 |
More Healthcare Companies
View all Healthcare →Put NVCT on your watchlist
Track score changes the day Nuvectis Pharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NVCT a good stock to buy?
13F Pro's AI-powered analysis of Nuvectis Pharma, Inc. (NVCT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NVCT are available on the NVCT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own NVCT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NVCT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Nuvectis Pharma, Inc.'s investment landscape.